KR20230024402A - E-셀렉틴 표적화를 통해 미세환경 매개 내성을 극복하기 위한 조성물 및 방법 - Google Patents

E-셀렉틴 표적화를 통해 미세환경 매개 내성을 극복하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230024402A
KR20230024402A KR1020237001653A KR20237001653A KR20230024402A KR 20230024402 A KR20230024402 A KR 20230024402A KR 1020237001653 A KR1020237001653 A KR 1020237001653A KR 20237001653 A KR20237001653 A KR 20237001653A KR 20230024402 A KR20230024402 A KR 20230024402A
Authority
KR
South Korea
Prior art keywords
subject
cancer
selectin
groups
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237001653A
Other languages
English (en)
Korean (ko)
Inventor
존 엘 마그나니
윌리엄 이 포글러
테오도르 스미스
Original Assignee
글리코미메틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글리코미메틱스, 인크. filed Critical 글리코미메틱스, 인크.
Publication of KR20230024402A publication Critical patent/KR20230024402A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020237001653A 2020-06-14 2021-06-11 E-셀렉틴 표적화를 통해 미세환경 매개 내성을 극복하기 위한 조성물 및 방법 Pending KR20230024402A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063038856P 2020-06-14 2020-06-14
US63/038,856 2020-06-14
US202063060605P 2020-08-03 2020-08-03
US63/060,605 2020-08-03
US202063198856P 2020-11-17 2020-11-17
US63/198,856 2020-11-17
PCT/US2021/036992 WO2021257398A1 (en) 2020-06-14 2021-06-11 Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Publications (1)

Publication Number Publication Date
KR20230024402A true KR20230024402A (ko) 2023-02-20

Family

ID=76731129

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001653A Pending KR20230024402A (ko) 2020-06-14 2021-06-11 E-셀렉틴 표적화를 통해 미세환경 매개 내성을 극복하기 위한 조성물 및 방법

Country Status (12)

Country Link
US (1) US20230218649A1 (https=)
EP (1) EP4164655A1 (https=)
JP (1) JP2023529485A (https=)
KR (1) KR20230024402A (https=)
CN (1) CN116033907A (https=)
AU (1) AU2021292458A1 (https=)
BR (1) BR112022025480A2 (https=)
CA (1) CA3181278A1 (https=)
IL (1) IL298977A (https=)
MX (1) MX2022015894A (https=)
WO (1) WO2021257398A1 (https=)
ZA (1) ZA202213322B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025143279A1 (ko) * 2023-12-26 2025-07-03 서울대학교병원 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2264043T3 (pl) 2005-09-02 2018-04-30 Glycomimetics, Inc. Heterobifunkcyjne inhibitory pan-selektyny
WO2009073911A1 (en) 2007-12-10 2009-06-18 Mater Medical Research Institute Treatment and prophylaxis
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
KR102055958B1 (ko) * 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
WO2015048616A1 (en) * 2013-09-30 2015-04-02 Glycomimetics, Inc. Methods and compositions for treating and/or preventing mucositis
JP6689854B2 (ja) 2014-12-03 2020-04-28 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US20200171005A9 (en) 2015-12-02 2020-06-04 Glycomimetics, Inc. Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker
AU2017341065B2 (en) 2016-10-07 2023-04-06 Crescent Biopharma, Inc. Highly potent multimeric E-selectin antagonists
JP7275131B2 (ja) * 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
KR20200128025A (ko) * 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020219419A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Multimeric pan–selectin antagonists
JP2022529806A (ja) 2019-04-24 2022-06-24 グリコミメティクス， インコーポレイテッド Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤
US20220265691A1 (en) 2019-07-12 2022-08-25 Glycomimetics, Inc. Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025143279A1 (ko) * 2023-12-26 2025-07-03 서울대학교병원 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법

Also Published As

Publication number Publication date
WO2021257398A1 (en) 2021-12-23
CN116033907A (zh) 2023-04-28
CA3181278A1 (en) 2021-12-23
EP4164655A1 (en) 2023-04-19
BR112022025480A2 (pt) 2023-01-17
MX2022015894A (es) 2023-01-24
ZA202213322B (en) 2024-04-24
AU2021292458A1 (en) 2023-01-19
US20230218649A1 (en) 2023-07-13
IL298977A (en) 2023-02-01
JP2023529485A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
Yawata et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells
KR102799514B1 (ko) 급성 골수성 백혈병(acute myeloid leukaemia) 치료를 위한 항 cd70-항체 argx-110의 용도
Xia et al. Angiogenic factors in chronic lymphocytic leukemia
Sun et al. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
RU2768186C2 (ru) Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
Huang et al. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia
Hou et al. Connective tissue growth factor stimulates osteosarcoma cell migration and induces osteosarcoma metastasis by upregulating VCAM-1 expression
KR102413412B1 (ko) 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도
Ji et al. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway
Paesler et al. Targeting the vascular endothelial growth factor in hematologic malignancies
KR20230024402A (ko) E-셀렉틴 표적화를 통해 미세환경 매개 내성을 극복하기 위한 조성물 및 방법
Franzolin et al. PlexinB1 inactivation reprograms immune cells in the tumor microenvironment, inhibiting breast cancer growth and metastatic dissemination
Alraouji et al. Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the β-catenin pathway
WO2021011435A1 (en) Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
US20240269157A1 (en) Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
WO2011088402A2 (en) The use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
CN113952453B (zh) Cxcr2抑制剂在制备治疗肿瘤的药物中的应用
JP2023527411A (ja) がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法
US20070203113A1 (en) Use of manzamine compounds in anti-cancer therapeutic regimens
WO2012037553A2 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
KR20250052364A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20250052368A (ko) 암의 치료 및/또는 예방을 위한 의약품
KR20250054778A (ko) 암의 치료 및/또는 예방을 위한 의약품

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240610

Comment text: Request for Examination of Application